These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A dopaminergic-cholinergic mechanism in production of psychotic symptoms. Friedhoff AJ; Alpert M Biol Psychiatry; 1973 Apr; 6(2):165-9. PubMed ID: 4709131 [No Abstract] [Full Text] [Related]
6. The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias). Marsden CD Mod Trends Neurol; 1975; 6():141-66. PubMed ID: 127927 [No Abstract] [Full Text] [Related]
7. Effects of histamine and histamine antagonists on the uptake and release of catecholamines and 5-HT in brain synaptosomes. Tuomisto J; Tuomisto L Med Biol; 1980 Feb; 58(1):33-7. PubMed ID: 7382578 [TBL] [Abstract][Full Text] [Related]
8. [Old and new thought concepts on the biochemical principles of psychopharmcotherapy]. Wunderlich H; Wunderlich HP Samml Zwangl Abh Geb Psychiatr Neurol; 1982; 50():61-80. PubMed ID: 6130615 [No Abstract] [Full Text] [Related]
9. Parkinsonism induced by dopaminergic antagonists. Hornykiewicz O Adv Neurol; 1975; 9():155-64. PubMed ID: 1096571 [No Abstract] [Full Text] [Related]
10. Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain. Raiteri M; Leardi R; Marchi M J Pharmacol Exp Ther; 1984 Jan; 228(1):209-14. PubMed ID: 6141277 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological properties of a new potential neuroleptic drug oxyprothepin. IV. Antiadrenergic action and influence on brain monoamines. Dlabac A; Metys J; Metysová J Act Nerv Super (Praha); 1971; 13(3):188-9. PubMed ID: 5113833 [No Abstract] [Full Text] [Related]
12. Coexisting tardive dyskinesia and parkinsonism: a case report. De Fraites EG; Davis KL; Berger PA Biol Psychiatry; 1977 Apr; 12(2):267-72. PubMed ID: 857938 [TBL] [Abstract][Full Text] [Related]
13. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism. Rinne UK; Sonninen V; Marttila R Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575 [TBL] [Abstract][Full Text] [Related]
14. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Frechilla D; Cobreros A; Saldise L; Moratalla R; Insausti R; Luquin M; Del Río J Synapse; 2001 Mar; 39(4):288-96. PubMed ID: 11169778 [TBL] [Abstract][Full Text] [Related]
15. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Kish SJ; Chang LJ; Mirchandani L; Shannak K; Hornykiewicz O Ann Neurol; 1985 Nov; 18(5):530-6. PubMed ID: 2416269 [TBL] [Abstract][Full Text] [Related]
16. Changes in brain neurotransmitters in rodent malaria. Roy S; Chattopadhyay RN; Maitra SK Indian J Malariol; 1993 Dec; 30(4):183-5. PubMed ID: 7913449 [TBL] [Abstract][Full Text] [Related]
17. Mianserin, an antidepressant with a unique neuropharmacological profile. Leonard BE Acta Psychiatr Belg; 1978; 78(5):770-80. PubMed ID: 35926 [No Abstract] [Full Text] [Related]
18. Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease. Altagracia M; Rojas P; Kravzov J; Rios C Proc West Pharmacol Soc; 1993; 36():289-91. PubMed ID: 7690973 [No Abstract] [Full Text] [Related]
19. Pharmacological properties of a potential tranquilising agent mesylphenacyrazine. I. Interaction with drugs influencing the nervous system. Metys J; Metysová J Act Nerv Super (Praha); 1974 Aug; 16(3):161. PubMed ID: 4153867 [No Abstract] [Full Text] [Related]
20. Some neurochemical effects of a new antianxiety agent centazolone. Laxmi CV; Dubey MP; Prasad CR; Dhawan BN Indian J Exp Biol; 1984 Dec; 22(12):649-52. PubMed ID: 6534856 [No Abstract] [Full Text] [Related] [Next] [New Search]